2012 Fiscal Year Final Research Report
The effect of anti-angiogenic therapy and antibody therapy for distant metastasis in osteosarcoma.
| Project/Area Number |
22591672
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Orthopaedic surgery
|
|---|
| Research Institution | Aichi Cancer Center Research Institute |
|---|
Principal Investigator |
SUGIURA Hideshi 愛知県がんセンター(研究所), 腫瘍免疫学部, 研究員 (50303615)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KYOGASHIMA Mamoru 日本薬科大学, 薬学部, 教授 (50225091)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Keywords | 骨 / 軟部腫瘍 |
|---|
| Research Abstract |
We evaluated the antitumor activity of anti-interleukin 2 receptor (IL2R) α(CD25) monoclonal antibody (PC61) or an anti-interleukin-2 monoclonal antibody (S4B6) in a murine osteosarcoma model (LM8). Tumors size and the numbers of lung and liver metastatic colonies were significantly decreased in both PC61 and S4B6 groups. Flow cytometry revealed that mouse regulatory T cells (Treg) can be deleted by intraperitoneal injection of PC61 or S4B6. Next, we examined the effectiveness of PC61 or S4B6 combined with Candesartan, but there were significantly no differences. It was suggested that PC61 and S4B6 strongly will suppress metastases and tumor progression.
|
